Contents

06 October 2010
Vol 2, Issue 52
  • Contents

    • Commentaries

      • Opening Up to Precompetitive Collaboration

        The move to increase biomedical R&D efficiency and innovation has stimulated the development of collaborations, among competitors, that span the precompetitive space.

      • The Bayh-Dole Act Turns 30

        The act that gave U.S. institutions the right to claim title to inventions resulting from federally funded work dramatically increased public benefits from research.

    • Research Articles

      • Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

        A human antibody to interleukin-17A is well tolerated and may be effective in the treatment of psoriasis, rheumatoid arthritis, and noninfectious uveitis.

      • PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease

        Abnormal expression of genes for energy regulation in Parkinson’s disease patients identifies a master regulator as a possible therapeutic target for early intervention.

    • Editors' Choice

      • Turning Off the Cancer Switch

        A new drug that blocks BMK1 inhibits tumor growth with minimal toxicity.

      • PANDERing to the Liver in Glucose Control

        A new cytokine-like protein produced by the pancreas regulates glucose production in the liver during fasting.

      • Bridging the Gap in Spinal Cord Injury

        Valproic acid coaxes transplanted neural stem cells to differentiate into neurons that boost repair of spinal cord injury in mice.

About The Cover

Cover image expansion

ONLINE COVER Cross Section Through the Skin of a Patient with the Inflammatory Skin Disease, Psoriasis. Dark red spots represent infiltrating T helper 17 cells, which are attracted by the cytokine IL-17A. Blocking this cytokine with a monoclonal antibody prevents infiltration of the skin by immune cells and ameliorates the inflammatory response in psoriasis patients as discussed by Hueber et al. this week. The skin section is stained with hematoxylin-eosin (epidermis, pink; dermis, blue). [CREDIT: ASIFA HAIDER, NOVARTIS]